Table 1 |
||||
|
Expression of IL-17 by mast cells, T cells and macrophages in synovial tissue |
||||
|
Demographics |
ACPA+ RA (n = 34) |
ACPA- RA (n = 25) |
OA (n = 29) |
P value |
|
|
||||
|
Age (years) |
55 (32 to 80) |
63 (19 to 80) |
67 (42 to 83) |
|
|
Gender (females/males) |
22/12 |
14/11 |
21/8 |
|
|
Disease duration (years) |
7 (0 to 28) |
8 (0 to 24) |
Unknown |
|
|
Median IL-17+ cells |
21 (0 to 118) |
12 (1 to 61) |
17 (0 to 50) |
0.381 |
|
IL-17+ mast cells (%) |
97 (40 to 100) |
96 (0 to 100) |
93 (0 to 100) |
0.969 |
|
IL-17+ T cells (%) |
0 (0 to 100) |
0 (0 to 24) |
2 (0 to 49) |
0.558 |
|
IL-17+ MØ (%) |
0 (0 to 78) |
4 (0 to 100) |
1 (0 to 58) |
0.382 |
|
Median MCs |
28 (0 to 123) |
19 (0 to 92) |
25 (0 to 76) |
0.198 |
|
MCs (CD117+) expressing IL-17 (%) |
91 (13 to 100) |
83 (0 to 100) |
96 (4 to 100) |
0.599 |
|
T cells (CD3+), n |
21 (0 to 592) |
10 (0 to 115) |
11 (0 to 265) |
0.609 |
|
T cells (CD3+) expressing IL-17 (%) |
0 (0 to 60) |
0 (0 to 66) |
1 (0 to 78) |
0.149 |
|
MØ (CD68+), n |
71 (1 to 390) |
53 (1 to 302) |
66 (2 to 231) |
0.634 |
|
MØ (CD68+) expressing IL-17 (%) |
0 (0 to 16) |
0 (0 to 14) |
0 (0 to 11) |
0.689 |
|
|
||||
|
ACPA: anticitrullinated protein antibody; MC: mast cell; MØ: macrophage; OA: osteoarthritis; RA: rheumatoid arthritis. Results are expressed as medians (minimum-maximum). Mast cells are defined as CD117+ cells, T cells are defined as CD3+ cells and macrophages are defined as CD68+ cells. |
||||
|
Suurmond et al. Arthritis Research & Therapy 2011 13:R150 doi:10.1186/ar3466 |
||||
